|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Molecular Oncology Program, H. Lee Moffitt
Cancer Center and Research Institute, Tampa, FL, and the Departments of
Interdisciplinary Oncology and Medical Microbiology and Immunology,
University of South Florida, Tampa.
In the blast crisis phase of chronic myelogenous leukemia (CML),
Bcr-Abl+ myeloblasts fail to undergo terminal maturation.
The extracellular signal-regulated kinase (Erk) mitogen-activated
protein (MAP) kinase has been shown to mediate terminal differentiation
of myeloid cells. Interestingly, Bcr-Abl+ CML cell lines
established from blast crisis were found to have low Erk MAP kinase
activity. In this study, we analyzed the role of the Gab2 docking
protein in regulation of the Erk MAP kinase in Bcr-Abl+
K562 human CML cells. Overexpression of Gab2 in K562 cells resulted in
transcriptional activation of the c-fos serum response
element (SRE) promoter, whereas overexpression of SHP2, Grb2, and CrkL had no effect. Activation of the c-fos SRE transcriptional
activity by Gab2 required tyrosine 604, which is a SHP2 docking site on Gab2, and the SHP2 tyrosine phosphatase activity. Elk1, c-Jun, and CHOP
trans-reporting assays indicated that overexpression of
Gab2 selectively activated the Erk2-Elk1 signaling pathway. To
determine cellular consequences of elevating the Gab2 level in K562
cells, stable cell lines for doxycycline-inducible expression of the
wild-type Gab2 (Gab2WT) and an SHP2-binding defective Gab2 (Gab2Tyr604Phe) were established. Analysis of these cell lines indicated that induction of Gab2WT expression, but not Gab2Tyr604Phe expression, led to Erk activation, growth arrest, cell spreading, and
enlargement; expression of megakaryocyte/platelet lineage-specific integrins Chronic myelogenous leukemia (CML) arises mostly
from the reciprocal t(9;22)(q34;q11) chromosomal translocation in
pluripotent hematopoietic stem cells.1-3 The
Bcr-Abl oncogene generated from the t(9;22)
chromosomal translocation encodes a p210Bcr-Abl protein
that has deregulated high tyrosine kinase activity and abnormal
cytoplasmic localization.1-6 The p210Bcr-Abl
activates the signaling pathways for signal transducer and activator of
transcription 5, phosphoinositide 3-kinase (PI3K), and Ras, thereby
conferring growth factor-independent proliferation and survival of
myeloid progenitor cells.7-11 Eventually, CML progresses from the chronic phase to the blast crisis phase, in which terminal differentiation of myeloid cells ceases.1,2,12 This leads to abnormal accumulation of immature leukemic blast cells in blood and
bone marrow.
Although the precise mechanism by which CML progresses from the chronic
phase to the blast crisis phase is largely unknown, Bcr-Abl+ CML cell lines established from patients in blast
crisis were found to have low or no detectable Erk MAP kinase
activity.13 Erk MAP kinase is known to mediate terminal
differentiation in several lineages of hematopoietic
cells.14-18 In particular, activation of the Erk MAP
kinase is required for maturation of erythromegakaryocytic progenitor
cells to megakaryocytes.17,18 In fact, activation of the
Erk MAP kinase by phorbol ester or by constitutively active MAP
kinase-Erk kinase-1 (MEK1) or MEK2 is sufficient to induce megakaryocytic differentiation of the K562 human CML
cells.19-21 These observations point to the possibility
that the low Erk MAP kinase activity in blast crisis CML cells may be a
mechanism responsible for their incomplete differentiation.
It is unclear why Bcr-Abl+ CML cell lines from blast crisis
have low Erk MAP kinase activity. Bcr-Abl tyrosine kinase is able to
activate the Ras-Raf-MEK-Erk signaling pathway in hematopoietic cells
in an experimental model system.10 The elevated platelet counts of CML patients during the chronic phase also indicated that
megakaryocyte progenitor cells can mature to functional megakaryocytes in this stage of the leukemia,1,12 suggesting that Erk MAP kinase is activated in these Bcr-Abl+ leukemic cells.
Therefore, the loss of Erk MAP kinase activity in CML blast crisis
cells is likely to be due to one or more secondary changes besides the
expression of Bcr-Abl tyrosine kinase.
Gab1 and Gab2 are pleckstrin homology domain-containing
multisite docking proteins.22-27 Gab1 was originally
isolated as a Grb2-binding protein from human glioma
cells22 and as a c-Met substrate in a yeast 2-hybrid
screen.23 Gab2 was originally observed as a 97-kd
tyrosine-phosphorylated protein associated with the SHP2 protein
tyrosine phosphatase (PTPase) in interleukin 3 (IL-3)-stimulated or
Bcr-Abl-transformed BaF3 and 32D cells.28 It was
subsequently purified and cloned from Bcr-Abl-transformed BaF3 cells
on the basis of its ability to bind SHP2.26 However, the
role of Gab2 in Bcr-Abl signaling has not been characterized.
Gab1 and Gab2 are constitutively associated with Grb2 through the
interaction between proline-rich sequences and the Grb2 carboxyl-terminal-SH3 domain.29 When Gab1 and Gab2 become
tyrosine phosphorylated in cells stimulated with several growth factors and cytokines, they bind SHP2, PI3K, CrkL, and Shc.26-34
Gab1-SHP2 interaction is required for Erk MAP kinase activation by
epidermal growth factor (EGF) and hepatocyte growth
factor,24,33 whereas Gab2-SHP2 interaction is involved in
IL-3-stimulated c-fos promoter activity.26 We
previously found that Bcr-Abl constitutively phosphorylates Gab2 in
K562 human CML cells.35 In the present study, we show
evidence that Gab2 is a critical signaling component controlling the
Erk MAP kinase activation and terminal differentiation of K562 cells.
Plasmids
A Gab2 containing Tyr604Phe mutation (pGab2Tyr604Phe) and a Gab2
containing triple Tyr-to-Phe mutations (Tyr441Phe, Tyr465Phe, Tyr574Phe; pGab2 Transient transfection assays
The PathDetect (Stratagene) trans-reporting
assays40 were performed by means of plasmids from
PathDetect in vivo Signal Transduction Pathway
trans-Reporting Systems according to the manufacturer's
instructions. For these experiments, K562 cells (2 × 106) were transfected with 3 µg testing construct
(pGab2WT, pGab2Tyr604Phe, or pcDNA3.1), along with 0.1 µg reporting
construct (pFA2-Elk1, pFA2-c-Jun, or pFA-CHOP), 1 µg pFR-luc
reporter, and 0.2 µg pCMV- Establishment of stable K562 cell lines pSTAR,41 a single-vector doxycycline (dox)-inducible expression system, was kindly provided by Dr Wanjin Hong. DNA fragments containing the FLAG-tagged Gab2WT, Gab2Tyr604Phe, and Gab2 PI3K were excised from the pcDNA3.1 constructs and subcloned
into the pSTAR vector to generate pSTAR-Gab2, pSTAR-Gab2Tyr604Phe, and pSTAR-Gab2PI3K. The pSTAR (empty vector control) and the pSTAR Gab2
constructs were linearized by Pvu I digestion. The
linearized DNA (5 µg for each experiment) was used to
transfect 1 × 106 K562 cells. At 24 hours after
transfection, cells were resuspended in fresh medium (RPMI 1640 with
10% tetracycline-free fetal bovine serum) containing 800 µg/mL G418
(Mediatech, Herndon, VA). Live cells were isolated from ficoll gradient
(Histopaque-1077) (Sigma, St Louis, MO) and cloned by limiting dilution
at a density of 0.5 cell per well in 96-well plates in medium
containing 800 µg/mL G418. G418-resistant clones were expanded and
screened for dox-inducible expression of the FLAG-tagged Gab2 by
immunoblotting analysis of cell lysates.
Flow cytometry analysis of CD41/CD61 expression The stable K562 cell lines (1 × 106 cells for each experiment) were induced with dox (4 µg/mL, 7 days) or left untreated. Cells were washed twice with PBS and blocked for 20 minutes in PBS containing 2% bovine serum albumin (BSA). Cells were then incubated with a fluorescein isothiocyanate (FITC)-conjugated antibody that reacts with the CD41/CD61 complex (mouse immunoglobulin (Ig)-G1, isotype, CD41a) (PharMingen, Franklin Lakes, NJ) or a
FITC-conjugated anti-CD61 antibody (mouse IgG1, isotype) in
50 µL wash buffer (PBS plus 1% BSA) for 30 minutes in the dark.
After incubation, cells were washed twice with the wash buffer and then
resuspended in 0.5 mL wash buffer before analyzing with a flow
cytometer. Fluorescent signal from 10 000 cells in each sample was
analyzed. Mouse IgG1, isotype control antibody was used in each condition.
For analysis of transiently transfected K562 cells, 2.5 × 106 cells for each experiment were transfected with 0.5 µg pDsRed1-C1 and 1.5 µg of each tested pSTAR construct. After transfection, cells were incubated with or without dox for 5 days. Cells were then processed for staining with the FITC-CD41a antibody and 7-amino-actinomycin D (7-AAD, PharMingen) and analyzed by flow cytometry. The 7-AAD-staining-positive (death) cells were excluded, and 1 × 104 RFP+ cells were gated for analysis of CD41+/CD61+ cells. Erk kinase assay K562 cells were incubated with or without 1 µg/mL dox for 18 hours. Cells (2 × 107) were lysed in buffer A (50 mM Tris [pH7.5], 150 mM NaCl, 1 mM EDTA, 1 mM ethyleneglycotetraacetic acid, 5 mM Na4PPi, 25 mM NaF, 1 mM Na3VO4, 2 µg/mL aprotinin, 2 µg/mL leupeptin, 100 µg/mL phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 20 mM P-nitrophenyl phosphate, and 1% Triton X-100). Cleared cell lysate supernatants were incubated with an anti-Erk2 MAP kinase antibody and protein-A agarose for 3 hours at 4°C. The immunoprecipitates were washed 4 times with buffer A. Erk MAP kinase activity in the immunoprecipitates was then determined by incubation of the immune complex with 40 µL reaction mixture (20 mM Hepes [pH 7.5], 10 mM MgCl2, 1 mM dithiothreitol, 10 mM P-nitrophenyl phosphate, 40 µM adenosine triphosphate [ATP], 0.375mg/mL myelin basic protein, and 10 µCi [0.37 MBq] [ -32P]ATP) for 10 minutes at 30°C.
The reaction was terminated with sodium dodecyl sulfate
(SDS)-containing gel-loading buffer and heat denaturation. The samples
were resolved on 11% SDS-polyacrylamide gels. Phosphorylation of
myelin basic protein was quantified by PhosphoImage (Molecular
Dynamics, Sunnyville, CA) analysis of the gel.
Immunoprecipitation and immunoblotting Cells were lysed in buffer B (25 mM Tris [pH7.2], 150 mM NaCl, 25 mM NaF, 1 mM Na3VO4, 2 µg/mL aprotinin, 2 µg/mL leupeptin, 100 µg/mL phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 20 mM P-nitrophenyl phosphate, and 1% Triton X-100). Immunoprecipitation and immunoblotting were performed essentially as described previously33,35 with the antibodies indicated in the figure legends. Anti-Gab2 antibody and horseradish peroxidase (HRP)-conjugated anti-Gab2 antibody were prepared as described.35 The sources of other antibodies were as provided previously.38Affymetrix microarray analysis Total RNA was isolated by means of the RNeasy kit (Qiagen, Valencia, CA). Double-stranded cDNA was synthesized from 20 µg total RNA by means of the Superscript Choice System (Life Technologies) with oligo (dT)24 primer containing T7 RNA polymerase promoter (Genset, La Jolla, CA). In vitro transcription was carried out by means of Bioarray High Yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY) with biotinylated cytidine triphosphate and uridine triphosphate. The biotin-labeled complementary RNA (cRNA) was purified with an RNeasy column and fragmented at 94°C for 35 minutes in fragmentation buffer (40 mM Tris-acetate [pH 8.1], 100 mM potassium acetate, 30 mM magnesium acetate). Integrity of total RNA, cDNA, cRNA, and fragmented cRNA was assessed by electrophoresis of the samples on 1% agarose gels.Microarray RNA analysis was performed according to the manufacturer's protocol by means of the HuGeneFL GeneChip (Affymetrix), which represents about 5600 known full-length human sequences. Scanned output files were visually inspected for hybridization artifacts and then analyzed with the Affymetrix Microarray 4.0 software. Arrays were scaled to an average intensity of 150 and analyzed independently. Genes were considered upregulated or downregulated if the expression was changed 2-fold from the control in both cell lines.
Ectopic expression of Gab2 in K562 cells upregulates the c-fos SRE promoter activity Gab2 is a substrate of Bcr-Abl tyrosine kinase and is constitutively tyrosine-phosphorylated in K562.35 Surprisingly, although K562 cells contain endogenous Gab2, expression of exogenous Gab2 resulted in about a 10-fold increase in the SRE transcriptional activity in K562 cells (Figure 1). This is in contrast to the effect of Gab2 in IL-3 signaling in BaF3 cells, in which overexpression of Gab2 did not further increase the IL-3-stimulated c-fos SRE transcriptional activity.26 Similarly, expression of exogenous Gab1 in COS-7 and HEK293 cells had only a small effect on Erk activation.33 As shown in Figure 1, expression of exogenous Gab1 in K562 cells also had a much smaller effect (3-fold activation) on the c-fos SRE transcriptional activity compared with that of Gab2 in parallel experiments.
We previously found that Tyr-627 of Gab1 was required for Gab1-SHP2
interaction in EGF-stimulated cells.33,38 The
corresponding residue in Gab2 is Tyr604. As shown in Figure
2, Tyr604 is required for Gab2-SHP2
interaction in K562 cells. Expression of Gab2Tyr604Phe reduced the
basal c-fos SRE transcriptional activity in K562 cells (Figure 1). Expression of a catalytically inactive SHP2 mutant (SHP2CS)
also decreased the basal c-fos SRE transcriptional activity in K562 cells. Thus, activation of the c-fos SRE
transcriptional activity by Gab2 required both Tyr604 of Gab2 and the
SHP2 PTPase activity.
In contrast to Gab2, overexpression of SHP2 had little effect on the c-fos SRE transcriptional activity (Figure 1). Coexpression of SHP2 with Gab2 also did not further increase the c-fos SRE transcriptional activity by Gab2. Grb2 and CrkL are 2 adapter proteins that interact with both Bcr-Abl and the Gab proteins.11,29,34,36,42 Figure 1 shows that overexpression of Grb2, CrkL, and the CrkL effector protein Rap1A did not increase the c-fos SRE transcriptional activity in K562 cells. Together, these observations suggest that activation of the c-fos SRE transcriptional activity in K562 cells is Gab2 specific. Gab2 is the limiting component of the Gab2-SHP2 complex To test whether Gab2 is the limiting component of the Gab2-SHP2 complex, we depleted Gab2 from K562 cell lysates by immunoprecipitation and then examined the SHP2 protein left in these cell lysates. K562 cell lysates were subjected to a repeated immunoprecipitation procedure with an anti-Gab2 antibody for 0 to 4 times. After immunodepletion of Gab2, the cleared cell lysates were used for secondary immunoprecipitation with an anti-SHP2 antibody. The amount of Gab2 or SHP2 protein in the immunoprecipitates was then analyzed by immunoblotting. Figure 2A (upper panel) shows that no Gab2 protein was detectable after the first Gab2 immunoprecipitation, indicating that all Gab2 protein had been removed from the cell lysates. The amounts of SHP2 protein immunoprecipitable from the K562 cell lysates were essentially the same regardless of whether or not Gab2 had been immunodepleted from these cell lysates (Figure 2A, lower panel). These data illustrate that SHP2 protein is present in large excess in the Gab2 protein in K562 cells; this is consistent with the notion that Gab2 is the limiting component of the Gab2-SHP2 complex necessary for Erk MAP kinase activation.To verify Tyr604 is required for Gab2-SHP2 interaction, we expressed FLAG-tagged Gab2WT and Gab2Tyr604Phe in K562 and analyzed coimmunoprecipitation of SHP2 with these 2 constructs. As shown in Figure 2B, SHP2 was coimmunoprecipitated with Gab2WT, but not with Gab2Tyr604Phe. This result indicates that Tyr604 is essential for Gab2-SHP2 interaction. Figure 2C shows that Gab1 is also expressed in K562 cells. Because no antibody could cross-react with both Gab1 and Gab2, we could not compare endogenous Gab1 and Gab2 proteins in K562 cells directly. To circumvent this problem, we performed repeated immunoprecipitation to immunoprecipitate all Gab1 and Gab2 proteins in K562 cells and then compared their tyrosine phosphorylation and SHP2 association. Figure 2C (lower panel) shows that essentially all Gab1 and Gab2 proteins were immunoprecipitated from K562 cell lysates after the first immunoprecipitation. Although Gab1 was tyrosine phosphorylated in K562 cells, Gab2 appeared to associate with several tyrosine-phosphorylated proteins that were not detected in the Gab1 immunoprecipitates (Figure 2C, upper panel). Furthermore, much less SHP2 was present in Gab1 immunoprecipitates than in Gab2 immunoprecipitates (Figure 2C, middle panel), suggesting that Gab1 might not be fully phosphorylated by Bcr-Abl in the SHP2 binding sites. These differences may account for the smaller effect of Gab1 on SRE transcriptional activity in K562 cells (Figure 1). Expression of Gab2 activates the Erk2-Elk1 signaling pathway in K562 cells The c-fos SRE binds a ternary complex consisting of serum response factor (SRF) and Elk1/TCF.40 Phosphorylation of Elk1 by the Erk MAP kinase in the C-terminal activation domain activates its transcriptional activity.40 To determine whether overexpression of Gab2 in K562 cells activates the Erk-Elk1 signaling pathway, we performed the Gal4-Elk1 trans-reporting assay.26,40,43 Parallel experiments were performed with the Gal4-c-Jun trans-reporting and the Gal4-CHOP trans-reporting assays to assess activation of the JNK MAP kinase and the p38 MAP kinase pathways in K562 cells.44,45As shown in Figure 3A, expression of Gab2
resulted in about 5-fold activation of the Gal4-Elk1
trans-reporter, whereas the Gal4-c-Jun
trans-reporter and the Gal4-CHOP trans-reporter
were not activated by Gab2 overexpression. The effect of Gab2 on
Gal4-Elk1 trans-reporter activation was dependent on the
amount of cDNA used for transfection (Figure 3B). Similar to what was
observed in the c-fos promoter assay, expression of
Gab2Tyr604Phe reduced the Gal4-Elk1 trans-reporter activity
to below the basal level (Figure 3B). To evaluate whether activation of
the Gal4-Elk1 trans-reporter activity is mediated by the Erk
MAP kinase, we treated transfected K562 cells with various
concentrations of an inhibitor (PD98059) for MEK1, the activator of
Erk2 MAP kinase (Erk1 is not expressed in K562 cells). As illustrated
in Figure 3C, PD98059 inhibited the Gab2-dependent Gal4-Elk1
trans-reporter activity at the lowest concentration tested
(5 µM) and completely blocked the Gab2-dependent Gal4-Elk1
trans-reporter activity at 50 µM. Furthermore,
coexpression of a dominant-negative Ras mutant (RasN17) with Gab2
completely blocked the Gal4-Elk1 trans-reporter
activity (Figure 3C). These data suggest that overexpression
of Gab2 in K562 cells resulted in selective activation of the
Erk2-Elk1 signaling pathway through a Ras-dependent mechanism.
Establishment of stable K562 cell lines for inducible expression of Gab2 and Gab2Tyr604Phe To assess the cellular consequence of Gab2 overexpression, we proceeded to establish stable K562 cell lines for dox-inducible expression of Gab2 constructs using the pSTAR vector.40 Linearized pSTAR-Gab2WT, pSTAR-Gab2Tyr604Phe, and the empty vector were transfected into K562 cells. G418-resistant cell lines were obtained by limiting dilution cloning in medium containing G418 without dox. G418-resistant cell lines were then further screened for dox-inducible expression of the Gab2 constructs. As shown in Figure 4B, we obtained 3 K562/pSTAR-Gab2 cell lines (Gab2WT-3, Gab2WT-6, and Gab2WT-7) and 2 K562/pSTAR-Gab2Tyr604Phe cell lines (Gab2Tyr604Phe-5 and Gab2Tyr604Phe-11) that showed dox-inducible expression of FLAG-tagged Gab2WT or Gab2Tyr604Phe. As predicted, FLAG-tagged Gab2 was not detected in a randomly selected G418-resistant cell line harboring the empty vector pSTAR (pSTAR-2) (Figure 4B). There was no apparent difference among these cell lines in p210Bcr-Abl protein (Figure 4A). Quantification of the relative amounts of endogenous and exogenous Gab2WT and Gab2Tyr604Phe proteins in these cell lines with a densitometer indicated that the exogenous Gab2WT and Gab2Tyr604Phe were overexpressed about 25-fold (Figure 4C). Figure 4D-E shows that Gab2WT in the 3 cell lines bound to the endogenous SHP2 when these cells were induced with dox. In contrast, although Gab2Tyr604Phe protein was expressed in dox-induced Gab2Tyr604Phe-5 and Gab2Tyr604Phe-11 cells, it did not bind SHP2.
To determine if induction of Gab2 expression in these lines affected Erk2 activity, these stable K562 cell lines were grown in the presence or absence of dox, and the endogenous Erk2 kinase activity was determined after immunoprecipition with an anti-Erk2 antibody. As shown in Figure 4F-H, dox treatment increased the constitutive Erk2 activity approximately 2-fold in the 3 K562 cell lines containing Gab2WT, but had no effect on Erk2 activity in the pSTAR-2 cells and the 2 cell lines containing Gab2Tyr604Phe. Overexpression of Gab2 in K562 leads to growth arrest and megakaryocytic differentiation Incubation of pSTAR-2 cells with dox had no apparent effect on cell proliferation (Figure 5A). In contrast, dox consistently induced growth arrest in the 3 K562 cell lines expressing Gab2WT (Figure 5B-D). Dox had a much smaller effect on proliferation of Gab2Tyr604Phe-5 and Gab2Tyr604Phe-11 cells expressing the SHP2-binding defective Gab2Tyr604Phe (Figure 5E-F). Gab2WT-expressing K562 cells appeared to become larger when they were grown in the presence of dox, and a fraction of the cells flattened and adhered to the plates (Figure 6). These morphological changes are similar to those of K562 cells treated with phorbol-12-myristate-13-acetate or transfected with constitutively active MEK1, which induces megakaryocyte lineage-specific differentiation of K562 cells by an Erk-dependent mechanism.19,46 The observed morphological changes were specific for K562 cells expressing the wild-type Gab2, because neither pSTAR-2 cells nor Gab2Tyr604Phe-5 cells (Figure 6) and Gab2Tyr604Phe-11 (not shown) underwent morphological changes when incubated with dox.
To determine if overexpression of Gab2 in K562 cells induced
megakaryocytic differentiation of these cells, we analyzed cell surface
expression of the megakaryocyte/platelet lineage-specific integrins
To further assess the effect of Gab2 overexpression on K562 cell
differentiation, we performed Affymetrix microarray analysis of the RNA
expression profile. To minimize clonal variations and experimental
errors, the same analysis was performed in 2 K562 cell lines, Gab2WT-6
and Gab2WT-7, that contain dox-inducible Gab2WT, and in pSTAR-2 cells
that contain vector control. Gab2WT-6, Gab2WT-7, and pSTAR-2 cells were
grown in medium with or without dox for 4 days. RNA expression profiles
of each cell line were analyzed with the HuGeneFL array. Table
1 lists 38 messenger RNA (mRNA) species
that were upregulated at least 2-fold in Gab2WT-6 and Gab2WT-7 cells by
dox induction. Two of these mRNA (CD44 and glycerol kinase) were also
upregulated at least 2-fold in the control pSTAR-2 cells and should be
considered nonspecific to Gab2 overexpression. Consistent with
increased surface expression of the megakaryocyte/platelet-specific
surface marker CD41/CD61, the CD41 and CD61 mRNAs were both upregulated
(Table 1).
Although the relevance of some of the mRNAs that were upregulated by
dox in Gab2WT-6 and Gab2WT-7 to K562 cell differentiation is unclear,
among mRNAs that were upregulated are those that encode known platelet
proteins: thrombospondin, plasminogen activator inhibitor-1, gelsolin,
CD69, SPARC/osteonectin, and placental protein 14 (Table 1).
Thrombospondin and plasminogen activator inhibitor-1 are known to be
synthesized in megakaryocytes and stored in the In addition, the levels of mRNA for IL-13 receptor, Smad7, and the dual-specificity protein phosphatase 5 were also increased by Gab2 overexpression (Table 1). IL-13 has been found to promote megakaryocyte colony formation.55 Smad7 was reported to inhibit erythroid leukemia cell differentiation.56 Dual-specificity protein phosphatase 5 (also called hVH-3) is an inducible Erk phosphatase.57,58 Therefore, the data from the microarray analysis appear to be consistent with the notion that Gab2 overexpression induced megakaryocytic differentiation of K562 cells. Removal of PI3K-binding sites in Gab2 does not affect the ability of Gab2 overexpression to induce CD41/CD61 expression in K562 cells Gab2 contains 3 potential PI3K-binding sites (Tyr441, Tyr465, and Tyr574).26,27 We constructed a Gab2 mutant (Gab2PI3K) in which these 3 Tyr residues were mutated to Phe. Transient expression experiments indicated that removal of these PI3K-binding sites did not
affect the ability of Gab2 to activate the c-fos SRE
promoter activity and Erk MAP kinase in K562 cells (data not shown).
However, attempts to establish stable K562 cell lines for dox-inducible expression of Gab2PI3K were not successful. As an alternative way to
compare the effects of Gab2WT and Gab2PI3K on K562 cell differentiation, K562 cells were cotransfected with pSTAR constructs and a plasmid for RFP, which served as a marker of transfected cells.
Transfected cells were cultured with or without dox and then stained
with an FITC-conjugated anti-CD41/CD61 antibody and 7-AAD.
CD41/CD61+ cells were analyzed in 7-AAD
(live), RFP+ (transfected) cell population by flow
cytometry. As shown in Figure 8, using
this approach, we were able to detect induction of CD41/CD61 expression
in K562 cells by Gab2WT, but not by the pSTAR vector control. These
results were consistent with the data obtained using the stable K562
cell lines and validated the methodology. Expression of Gab2PI3K
caused a similar induction of CD41/CD61 expression in K562 cells as
expression of Gab2WT. Therefore, elimination of PI3K-binding sites in
Gab2 did not appear to affect its activity to induce CD41/CD61
expression in K562 cells. In addition, parallel experiments showed that
overexpression of Gab1 did not induce CD41/CD61 expression in K562
cells (Figure 8).
Although Gab2 was originally isolated and cloned from Bcr-Abl-transformed hematopoietic cells,26 the role of Gab2 in cell signaling and its function in Bcr-Abl+ hematopoietic cells has not been characterized previously. Gab2 is readily phosphorylated by Abl tyrosine kinase in vitro (data not shown) and is constitutively phosphorylated by Bcr-Abl in K562 cells. Therefore, we used K562 cells as a model to investigate the role of Gab2 in Bcr-Abl+ CML cells. Similar to what was observed in IL-3-stimulated pre-B cells,26 both the SHP2 docking site on Gab2 and the SHP2 PTPase activity were found to be required for the basal c-fos SRE transcriptional activity in K562 cells. Tyr604 of Gab2 was found to mediate SHP2 binding to Gab2 in K562 cells. However, we have not completely ruled out the possibility that Tyr604 may also serve as a docking site for another uncharacterized SH2 domain-containing protein. Interestingly, while overexpression of Gab2 in BaF3 cells did not increase the IL-3-stimulated c-fos SRE transcriptional activity, overexpression of Gab2 in K562 cells markedly increased c-fos SRE transcriptional activity. Because overexpression of other Gab2-binding partners (Grb2, SHP2, and CrkL) that have been implicated in Bcr-Abl signaling or the Ras-MAP kinase pathway had little effect on c-fos promoter activity, our observation suggests that Gab2 is a signaling-threshold protein that limits c-fos SRE transcriptional activity in K562 cells. Indeed, our Gab2 immunodepletion experiment demonstrates that SHP2 protein exceeds Gab2 protein in K562 cells, confirming that Gab2 is the limiting factor for the Gab2-SHP2 complex in K562 cells. Interestingly, while Gab1 is expressed in K562 cells and in normal megakaryocytes and erythroid progenitors,32,59,60 it did not appear to have the same effect as Gab2 in mediating c-fos promoter activation and CD41/CD61 expression in K562 cells. Comparison of endogenous Gab1 and Gab2 proteins in K562 cells suggests that Gab1 does not appear to be more abundant in K562 cells. Rather, Gab1 binds a lower amount of SHP2 than Gab2 does in K562 cells. Gab2 also interacts with several tyrosine-phosphorylated proteins that were not detected in Gab1 immunoprecipitates. The PathDetect trans-reporting assays showed that overexpression of Gab2 selectively activated the Erk2-Elk1 pathway in K562 cells. The involvement of the Ras-Raf-MEK-Erk pathway in Elk1 activation in our assay was confirmed with the use of the well-characterized MEK1 inhibitor PD98059 and the dominant-negative RasN17 mutant. Furthermore, the effect of Gab2 overexpression on Erk2 activation was directly demonstrated in the 3 stable K562 cell lines expressing Gab2WT. Analysis of the dox-inducible stable K562 cell lines showed that overexpression of wild-type Gab2 in K562 cells induced growth arrest, cell flattening, expression of megakaryocytic-specific cell surface markers CD41/CD61, and upregulation of RNA for megakaryocyte/platelet proteins. These results provide additional evidence to support the notion that overexpression of Gab2 in K562 cells activates the Erk MAP kinase pathway in these cells. Overexpression of Gab2 induces K562 cell growth arrest and differentiation, which require Tyr604 of Gab2. However, expression of Gab2Tyr604Phe did not result in stimulation of K562 cell proliferation. One possibility is that, although constitutive Erk activation caused by Gab2 overexpression inhibits K562 cell proliferation, basal or transient Erk activity is involved in K562 cell proliferation. Indeed, incubation of parental K562 cells with the MEK1 inhibitor PD98059 partially reduced the growth rate of K562 cells (data not shown). Different cellular consequences mediated by sustained versus transient Erk activation have been documented previously in PC12 cells.61 While the low basal Erk2 activity in K562 cells precluded detection of inhibition of Erk2 by Gab2Tyr604Phe, the Elk1 trans-reporter and c-fos-promoter luciferase assays showed that Gab2Tyr604Phe had a inhibitory effect on the basal activities of these reporters in K562 cells. Therefore, inhibition of the basal Erk2 activity by Gab2Tyr604Phe does not necessarily give rise to a higher proliferation rate. In short, constitutive Erk activation mediates inhibition of K562 cell proliferation, but inhibition of Erk activity will not stimulate K562 cell proliferation. We have recently shown that Gab1-SHP2 interaction activates the SHP2 PTPase, which is required for Erk MAP kinase activation by EGF-receptor tyrosine kinases.38 Because of the similar bisphosphoryl tyrosine-based activation motifs found in the C-terminal regions of Gab1 and Gab2, it is conceivable that Gab2-SHP2 interaction also activates the SHP2 PTPase. However, it remains unknown which tyrosine-phosphorylated protein must be dephosphorylated by SHP2 to permit Erk activation. A potential SHP2 substrate is Gab2 itself. Gab2 contains several optimal Abl tyrosine kinase phosphorylation sites26,62 and is highly phosphorylated by Bcr-Abl in K562 cells. Furthermore, SHP2 can dephosphorylate Gab2.27 However, other possible targets, such as a Gab2-associated protein or a protein localized in the proximity of the Gab2-SHP2 complex, cannot be excluded. Although the mechanism by which Gab2 mediates Erk MAP kinase activation requires further investigation, our experiments demonstrate that Gab2 has a critical role in the Erk MAP kinase pathway in Bcr-Abl+ K562 CML cells. Because of secondary changes, therapeutic approaches besides the inhibition of Bcr-Abl tyrosine kinase activity are necessary for the majority of CML patients in blast crisis.63 Interestingly, many leukemic cells, like K562 cells, retain the potential for some degree of terminal differentiation and can be reprogrammed to differentiate and stop proliferating.17,19,20,64-66 Our study identifies Gab2 as a key signaling-threshold factor that controls the terminal differentiation of K562 cells and as a potential molecular target for attenuating leukemic cell proliferation. It will be interesting to see, through further studies, what fractions of primary CML cells share the same deficit in Gab2 expression as the human K562 CML cells and can be reprogrammed to differentiation by Gab2 expression.
We thank Drs John Groffen, Wanjin Hong, and Richard Jove for reagents, and Dr Kapil Bhalla for critical reading of the manuscript. We also acknowledge Moffitt Cancer Center Core Facilities for assistance in DNA sequence, microarray, flow cytometry, and statistical analyses, especially Judi Kroeger for flow cytometry analysis.
Submitted May 17, 2001; accepted October 11, 2001.
Supported by American Cancer Society Grant RPG0028901TBE and by National Institutes of Health grant CA77467.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Jie Wu, Molecular Oncology Program, MRC 3-East, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612; e-mail: wu{at}moffitt.usf.edu.
1.
Sawyers CL.
Chronic myeloid leukemia.
New Engl J Med.
1999;340:1330-1340 2. Pasternak G, Hochhaus A, Schultheis B, Hehlmann R. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol. 1998;124:643-660[CrossRef][Medline] [Order article via Infotrieve].
3.
Daley G, ven Etten R, Baltimore D.
Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome.
Science.
1990;247:824-830
4.
Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON.
Unique forms of the abl tyrosine kinase distinquish Ph1-positive CML from Ph1-positive ALL.
Science.
1987;235:85-88
5.
McWhirter JR, Wang JYJ.
Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
Mol Cell Biol.
1991;11:1553-1565 6. McWhirter JR, Wang JYJ. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene. 1997;15:1625-1634[CrossRef][Medline] [Order article via Infotrieve].
7.
Horita M, Andreu EJ, Benito A, et al.
Blockage of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-XL.
J Exp Med.
2000;191:977-984
8.
Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD.
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.
Blood.
2000;95:2118-2125
9.
Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL.
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles of phosphatidylinositol 3-kinase and Raf.
Mol Cell Biol.
2000;20:1179-1186 10. Cortez D, Reuter G, Pendergast AM. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997;15:2333-2342[CrossRef][Medline] [Order article via Infotrieve].
11.
Million RP, Van Etten RA.
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
Blood.
2000;96:664-670
12.
Druker BJ, Talpaz M, Resta DJ, et al.
Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia.
N Engl J Med.
2001;344:1031-1037
13.
Morgan MA, Dolp O, Reuter CWM.
Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid cell lines and induction of growth inhibition and apoptosis by inhibitors of Ras signaling.
Blood.
2001;97:1823-1834 14. Alberola-Ila J, Forbush KA, Seger R, Krebs EG, Perlmutter RM. Selective requirement for MAP kinase activation in thymocyte differentiation. Nature. 1995;373:620-623[CrossRef][Medline] [Order article via Infotrieve]. 15. Crompton T, Gilmour KC, Owen MJ. The MAP pathway controls differentiation from double-negative to double-positive thymocyte. Cell. 1996;86:243-251[CrossRef][Medline] [Order article via Infotrieve]. 16. Iritani BM, Forbush KA, Farrar MA, Permutter R. Control of B cell development by Ras-mediated activation of Raf. EMBO J. 1997;16:7019-7031[CrossRef][Medline] [Order article via Infotrieve].
17.
Melemed AS, Ryder JW, Vik TA.
Activation of the mitogen-activated protein kinase pathway is involved in and sufficient for megakaryocytic differentiation of CMK cells.
Blood.
1997;90:3462-3470
18.
Fichelson S, Freyssinier JM, Picard F, et al.
Megakaryocyte growth and development factor-induced proliferation and differentiation are regulated by the mitogen-activated protein kinase pathway in primitive cord blood hematopoietic progenitors.
Blood.
1999;94:1601-1613 19. Whalen AS, Galasinski C, Shapiro PS, Nahreini TS, Ahn NG. Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol. 1997;17:1947-1958[Abstract].
20.
Racke FK, Lewandowska K, Goueli S, Goldfarb AN.
Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells.
J Biol Chem.
1997;272:23366-23370 21. Herrera R, Hubbell S, Decker S, Petruzzelli L. A role for the MEK/MAPK pathway in PMA-induced cell cycle arrest: modulation of megakaryocytic differentiation of K562 cells. Exp Cell Res. 1998;238:407-414[CrossRef][Medline] [Order article via Infotrieve]. 22. Holgado-Madruga M, Emlet DR, Moscatello DK, Godwin AK, Wong AJ. A Grb2-associated docking protein in EGF- and insulin-receptor signaling. Nature. 1996;379:560-564[CrossRef][Medline] [Order article via Infotrieve]. 23. Weidner KM, Cesare SD, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 1996;384:173-176[CrossRef][Medline] [Order article via Infotrieve].
24.
Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M.
The tyrosine phosphatase SHP2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase.
Mol Cell Biol.
2000;20:8513-8525
25.
Takahashi-Tezuka M, Yoshida Y, Fukada T, et al.
Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to Erk mitogen-activated protein kinase.
Mol Cell Biol.
1998;18:4109-4117 26. Gu H, Pratt JC, Burakoff SJ, Neel B. Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell. 1998;2:729-740[CrossRef][Medline] [Order article via Infotrieve].
27.
Nishida K, Yoshida Y, Itoh M, et al.
Gab-family adapter protein act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors.
Blood.
1999;93:1809-1816
28.
Gu H, Griffin JD, Neel BG.
Characterization of two SHP2-associated binding proteins and potential substrates in hematopoietic cells.
J Biol Chem.
1997;272:16421-16430
29.
Lock LS, Royal I, Naujokas MA, Park M.
Identification of an atypical Grb2 carboxyl-terminal SH2 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases.
J Biol Chem.
2000;275:31536-31545
30.
Gu H, Maeda H, Moon JJ, et al.
New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway.
Mol Cell Biol.
2000;20:7109-7120
31.
Shi Z-Q, Yu D-H, Park M, Marshall M, Feng G-S.
Molecular mechanism for the SHP2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity.
Mol Cell Biol.
2000;20:1526-1536
32.
Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K.
Thrombopoietin induces phosphoinositol 3- kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes.
J Biol Chem.
2001;276:2494-2502
33.
Cunnick JM, Dorsey JF, Munoz-Antonia T, Mei L, Wu J.
Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor.
J Biol Chem.
2000;275:13842-13848
34.
Sakkab D, Lewitzky M, Posern G, et al.
Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CrkL.
J Biol Chem.
2000;275:10772-10778
35.
Dorsey JF, Jove R, Kraker AJ, Wu J.
The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells.
Cancer Res.
2000;60:3127-3131
36.
Ten Hoeve J, Kaartinen V, Fioretos T, et al.
Cellular interaction of CrkL, an SH2-SH3 adaptor protein.
Cancer Res.
1994;54:2563-2567
37.
Suen K, Bustelo XR, Pawson T, Barbacid M.
Molecular cloning of the mouse grb2 gene: differential interaction of the Grb2 adaptor protein with epidermal growth factor and nerve growth factor receptors.
Mol Cell Biol.
1993;13:5500-5512
38.
Cunnick JM, Mei L, Doupnik CA, Wu J.
Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2.
J Biol Chem.
2001;276:24380-24387
39.
Cunnick JM, Dorsey JF, Standley T, et al.
Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway.
J Biol Chem.
1998;273:14468-14475 40. Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell. 1993;73:381-393[CrossRef][Medline] [Order article via Infotrieve]. 41. Zeng Q, Tan YH, Hong W. A single plasmid vector (pSTAR) mediating efficient tetracycline-induced gene expression. Anal Biochem. 1998;259:187-194[CrossRef][Medline] [Order article via Infotrieve]. 42. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for Bcr-Abl-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541[Abstract].
43.
Zhao C, Yu D-H, Shen R, Feng G-S.
Gab2, a new pleckstrin homology domain-containing adapter protein, acts to uncouple signaling from ERK kinase to Elk-1.
J Biol Chem.
1999;274:19649-19699 44. Garcia-Guzman M, Dolfi F, Zeh K, Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation. Oncogene. 1999;18:7775-7786[CrossRef][Medline] [Order article via Infotrieve]. 45. Wang XZ, Ron D. Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science. 1996;272:1347-1349[Abstract]. 46. Lee CH, Yun HJ, Kang HS, Kim HD. Erk/MAPK pathway is required for changes of cyclin D1 and B1 during phorbol 12-myristate 13-acetate-induced differentiation of K562 cells. IUBMB Life. 1999;48:585-591[CrossRef][Medline] [Order article via Infotrieve].
47.
Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ, Hasty KA, Hall CL.
Tissue factor pathway inhibitor binds to platelet thrombospondin-1.
J Biol Chem.
2000;275:31715-31721
48.
Bonnefoy A, Hantgan R, Legrand C, Frojmovic MM.
A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen and GPIIbIIIa receptor.
J Biol Chem.
2000;276:5605-5612
49.
Hill SA, Shaughnessy SG, Joshua P, Ribau J, Austin RC, Podor TJ.
Differential mechanisms targeting type-1 plasminogen activator inhibitor and vitronectin into the storage granules of a human megakaryocytic cell line.
Blood.
1996;87:5061-5073 50. Bearer EL, Prakash JM, Manchester RD, Allen PG. VASP protects actin filaments from gelsolin: an in vitro study with implications for platelet actin reorganization. Cell Motil Cytoskeleton. 2000;47:351-364[CrossRef][Medline] [Order article via Infotrieve].
51.
Palet H, Barkalow KL, Pivniouk VI, Barnes MJ, Geha RS, Hartwig JH.
Roles of SLP-76, phosphoinositide 3-kinase, and gelsolin in the platelet shape changes initiated by the collagen receptor GPVI/FcR g-chain complex.
Blood.
2000;96:3786-3792
52.
Testi R, Pulcinelli F, Frati L, Gazzaniga PP, Santoni A.
CD69 is expressed on platelets and mediates platelet activation and aggregation.
J Exp Med.
1990;172:701-707
53.
Kelm RJ, Hair GA, Mann KG, Grant BW.
Characterization of human osteoblast and megakaryocyte-derived osteonectin (SPARC).
Blood.
1992;80:3112-3119 54. Tykocinski ML, Xiong N, Morrow DM. Platelet immunoregulatory factors. Stem Cells. 1996;14(suppl 1):240-245. 55. Xi X, Schlegel N, Caen JP, et al. Differential effects of recombinant human interleukin-13 on the in vitro growth of human haemopoietic progenitor cells. Br J Haematol. 1995;90:921-927[Medline] [Order article via Infotrieve].
56.
Kitamura K, Aota S, Sakamoto R, Yoshikawa SI, Okazaki K.
Smad7 selectively interferes with different pathways of activin signaling and inhibits erythroid leukemia cell differentiation.
Blood.
2000;95:3371-3379
57.
Ishibashi T, Bottaro DP, Michieli P, Kelley CA, Aaronson SA.
A novel dual specificity phosphatase induced by serum stimulation and heat shock.
J Biol Chem.
1994;269:29897-29902
58.
Kwak S, Dixon JE.
Multiple dual specificity protein tyrosine phosphatases are expressed and regulated differentially in liver cell lines.
J Biol Chem.
1995;270:1156-1160 59. Bouscary D, Lecoq-Lafon C, Chretien S, et al. Role of Gab proteins in phosphatidylinositol 3- kinase activation by thrombopoietin (Tpo). Oncogene. 2001;20:2197-2204[CrossRef][Medline] [Order article via Infotrieve].
60.
Lecoq-Lafon C, Verdier F, Fichelson S, et al.
Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase.
Blood.
1999;93:2578-2585 61. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179-186[CrossRef][Medline] [Order article via Infotrieve]. 62. Songyang Z, Carraway KL III, Eck MJ, et al. Catalytic specificity of protein tyrosine kinases is critical for selective signaling. Nature. 1995;373:536-539[CrossRef][Medline] [Order article via Infotrieve].
63.
Druker BJ, Sawyers CL, Kantarjian H, et al.
Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Phildelphia chromosome.
N Engl J Med.
2001;344:1038-1042
64.
Matushansky I, Radparvar F, Skoultchi AI.
Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1.
Proc Natl Acad Sci U S A.
2000;97:14317-14322 65. Makishima M, Honma Y, Hozumi M, Sampi K, Hattori M, Motoyoshi K. Induction of differentiation of human leukemia cells by inhibitors of myosin light chain kinase. FEBS Lett. 1991;287:175-177[CrossRef][Medline] [Order article via Infotrieve]. 66. Wang X, Studzinski GP. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J Cell Biochem. 2001;80:471-482[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. Pyarajan, G. Matejovic, J. C. Pratt, S. Baksh, and S. J. Burakoff Interleukin-3 (IL-3)-induced c-fos Activation Is Modulated by Gab2-Calcineurin Interaction J. Biol. Chem., August 29, 2008; 283(35): 23505 - 23509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ren, Z. Chen, L. Chen, N. T. Woods, G. W. Reuther, J. Q. Cheng, H.-g. Wang, and J. Wu Shp2E76K Mutant Confers Cytokine-independent Survival of TF-1 Myeloid Cells by Up-regulating Bcl-XL J. Biol. Chem., December 14, 2007; 282(50): 36463 - 36473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Juric, N. J. Lacayo, M. C. Ramsey, J. Racevskis, P. H. Wiernik, J. M. Rowe, A. H. Goldstone, P. J. O'Dwyer, E. Paietta, and B. I. Sikic Differential Gene Expression Patterns and Interaction Networks in BCR-ABL-Positive and -Negative Adult Acute Lymphoblastic Leukemias J. Clin. Oncol., April 10, 2007; 25(11): 1341 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lennartsson, R. Shivakrupa, and D. Linnekin Synergistic Growth of Stem Cell Factor and Granulocyte Macrophage Colony-stimulating Factor Involves Kinase-dependent and -independent Contributions from c-Kit J. Biol. Chem., October 22, 2004; 279(43): 44544 - 44553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-S. Zhu, L. J. Robinson, V. Roginskaya, and S. J. Corey G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses Blood, May 1, 2004; 103(9): 3305 - 3312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ren, S. Meng, L. Mei, Z. J. Zhao, R. Jove, and J. Wu Roles of Gab1 and SHP2 in Paxillin Tyrosine Dephosphorylation and Src Activation in Response to Epidermal Growth Factor J. Biol. Chem., February 27, 2004; 279(9): 8497 - 8505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Vijayan, Y. Liu, J.-F. Dong, and P. F. Bray Enhanced Activation of Mitogen-activated Protein Kinase and Myosin Light Chain Kinase by the Pro33 Polymorphism of Integrin beta 3 J. Biol. Chem., January 31, 2003; 278(6): 3860 - 3867. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
IIb/
3 (CD41/CD61); and upregulation of RNA for
megakaryocyte/platelet proteins. All of these changes are
characteristics of megakaryocytic differentiation. Together, these
results reveal Gab2 as a limiting signaling component for Erk MAP
kinase activation and terminal differentiation of K562 CML cells.
(Blood. 2002;99:1388-1397)
